Why did ALNEV.PA stock drop today?

ALNEV.PA stock fell due to heavy selling, weak fundamentals and thin liquidity. Intraday volume surged to **9,172,848** and market reaction focused on ongoing losses and cash constraints.

What is Meyka AI's rating for ALNEV.PA stock?

Meyka AI rates ALNEV.PA **62.03/100 (Grade B, HOLD)**. The score combines sector, financial growth, key metrics and analyst consensus. Grades are informational, not investment advice.

What price targets exist for ALNEV.PA stock?

Short‑term scenario targets: base **€0.0012**, bull **€0.0040**, bear **€0.0005**. Targets reflect high volatility, microcap status and trial/financing outcomes.

How liquid is ALNEV.PA stock on EURONEXT?

Liquidity is limited despite a recent spike. Avg volume is **6,651,337**; today’s volume was **9,172,848**. Low market cap (**€1,192.00**) increases execution risk for larger orders.

EU Stocks

ALNEV.PA stock down 14.29% intraday on EURONEXT 09 Feb 2026: market risks ahead

ByHuzaifa Zahoor February 9, 2026February 9, 2026

ALNEV.PA stock fell intraday 14.29% to €0.0024 on EURONEXT on 09 Feb 2026, making it one of the top losers in Europe’s healthcare list. Trading volume hit 9,172,848 shares, above the 3‑month average, and the session low was €0.0023. Investors reacted to continued cash strain, negative earnings metrics and thin liquidity. Below we break down the drivers, valuation, technicals and short-term outlook for Neovacs S.A. (ALNEV.PA stock) using real-time metrics and Meyka AI analysis.